ShockWave Medical, Inc. (NASDAQ:SWAV) Director Frank T. Watkins Sells 2,000 Shares of Stock

ShockWave Medical, Inc. (NASDAQ:SWAV) Director Frank T. Watkins sold 2,000 shares of the business’s stock in a transaction dated Tuesday, November 16th. The stock was sold at an average price of $208.41, for a total transaction of $416,820.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

NASDAQ SWAV opened at $206.64 on Friday. The company has a quick ratio of 5.65, a current ratio of 6.36 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $7.30 billion, a PE ratio of -187.85 and a beta of 1.25. The company has a 50 day moving average price of $213.39 and a two-hundred day moving average price of $193.09. ShockWave Medical, Inc. has a 12-month low of $84.24 and a 12-month high of $249.73.

ShockWave Medical (NASDAQ:SWAV) last posted its earnings results on Monday, November 8th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.07) by $0.12. The firm had revenue of $65.16 million during the quarter, compared to analysts’ expectations of $61.21 million. ShockWave Medical had a negative net margin of 21.60% and a negative return on equity of 17.68%. The company’s revenue was up 232.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.38) earnings per share. As a group, equities analysts anticipate that ShockWave Medical, Inc. will post -0.54 EPS for the current year.

Several institutional investors have recently modified their holdings of the company. PNC Financial Services Group Inc. lifted its stake in shares of ShockWave Medical by 30.3% in the third quarter. PNC Financial Services Group Inc. now owns 202 shares of the company’s stock worth $41,000 after buying an additional 47 shares during the last quarter. Wellington Management Group LLP increased its stake in ShockWave Medical by 2.1% during the third quarter. Wellington Management Group LLP now owns 2,565 shares of the company’s stock valued at $528,000 after acquiring an additional 53 shares during the period. Kovack Advisors Inc. increased its stake in ShockWave Medical by 5.4% during the third quarter. Kovack Advisors Inc. now owns 1,475 shares of the company’s stock valued at $304,000 after acquiring an additional 75 shares during the period. Truist Financial Corp increased its stake in ShockWave Medical by 2.8% during the third quarter. Truist Financial Corp now owns 3,827 shares of the company’s stock valued at $788,000 after acquiring an additional 103 shares during the period. Finally, Berman Capital Advisors LLC increased its stake in ShockWave Medical by 63.0% during the third quarter. Berman Capital Advisors LLC now owns 300 shares of the company’s stock valued at $61,000 after acquiring an additional 116 shares during the period. Institutional investors and hedge funds own 91.37% of the company’s stock.

Several equities analysts have recently issued reports on the stock. Piper Sandler lifted their price objective on shares of ShockWave Medical from $225.00 to $272.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 9th. Canaccord Genuity lifted their target price on shares of ShockWave Medical from $219.00 to $258.00 and gave the stock a “buy” rating in a research report on Tuesday, November 9th. SVB Leerink boosted their price objective on shares of ShockWave Medical from $250.00 to $265.00 and gave the company an “outperform” rating in a research report on Tuesday, November 9th. Wells Fargo & Company boosted their price objective on shares of ShockWave Medical from $200.00 to $235.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 9th. Finally, Morgan Stanley boosted their price objective on shares of ShockWave Medical from $152.00 to $200.00 and gave the company an “equal weight” rating in a research report on Tuesday, August 10th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, ShockWave Medical currently has a consensus rating of “Hold” and a consensus price target of $237.86.

About ShockWave Medical

Shockwave Medical, Inc operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease.

Read More: What are the economic characteristics of a bear market?

Insider Buying and Selling by Quarter for ShockWave Medical (NASDAQ:SWAV)

Receive News & Ratings for ShockWave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShockWave Medical and related companies with MarketBeat.com's FREE daily email newsletter.